1AVF | A:172-327; J:172-328; A:2-171; J:2-171 | ACTIVATION INTERMEDIATE 2 OF HUMAN GASTRICSIN FROM HUMAN STOMACH |
1BBS | A:171-325; A:1-170 | X-RAY ANALYSES OF PEPTIDE INHIBITOR COMPLEXES DEFINE THE STRUCTURAL BASIS OF SPECIFICITY FOR HUMAN AND MOUSE RENINS |
1BIL | A:171-325; B:171-325; B:1-170; A:1-170 | CRYSTALLOGRAPHIC STUDIES ON THE BINDING MODES OF P2-P3 BUTANEDIAMIDE RENIN INHIBITORS |
1BIM | A:171-325; B:171-325; B:1-170; A:1-170 | CRYSTALLOGRAPHIC STUDIES ON THE BINDING MODES OF P2-P3 BUTANEDIAMIDE RENIN INHIBITORS |
1FKN | A:14-146; B:14-146; A:147-385; B:147-385 | STRUCTURE OF BETA-SECRETASE COMPLEXED WITH INHIBITOR |
1FLH | A:171-325; A:1-170 | CRYSTAL STRUCTURE OF HUMAN UROPEPSIN AT 2.45 A RESOLUTION |
1HRN | A:171-325; B:171-325; B:1-170; A:1-170 | HIGH RESOLUTION CRYSTAL STRUCTURES OF RECOMBINANT HUMAN RENIN IN COMPLEX WITH POLYHYDROXYMONOAMIDE INHIBITORS |
1HTR | B:172-328; B:1-171 | CRYSTAL AND MOLECULAR STRUCTURES OF HUMAN PROGASTRICSIN AT 1.62 ANGSTROMS RESOLUTION |
1LYA | A:1-97; C:1-97; B:106-346; D:106-346 | CRYSTAL STRUCTURES OF NATIVE AND INHIBITED FORMS OF HUMAN CATHEPSIN D: IMPLICATIONS FOR LYSOSOMAL TARGETING AND DRUG DESIGN |
1LYB | A:1-97; C:1-97; B:106-346; D:106-346 | CRYSTAL STRUCTURES OF NATIVE AND INHIBITED FORMS OF HUMAN CATHEPSIN D: IMPLICATIONS FOR LYSOSOMAL TARGETING AND DRUG DESIGN |
1LYW | A:3-97; C:3-97; E:3-97; G:3-97; B:106-346; D:106-346; F:106-346; H:106-346 | CATHEPSIN D AT PH 7.5 |
1M4H | A:14-146; A:147-385; B:147-385; B:14-146 | CRYSTAL STRUCTURE OF BETA-SECRETASE COMPLEXED WITH INHIBITOR OM00-3 |
1PSN | A:171-325; A:1-170 | THE CRYSTAL STRUCTURE OF HUMAN PEPSIN AND ITS COMPLEX WITH PEPSTATIN |
1PSO | E:171-325; E:1-170 | THE CRYSTAL STRUCTURE OF HUMAN PEPSIN AND ITS COMPLEX WITH PEPSTATIN |
1Q9P | A:1-95 | SOLUTION STRUCTURE OF THE MATURE HIV-1 PROTEASE MONOMER |
1QRP | E:171-325; E:1-170 | HUMAN PEPSIN 3A IN COMPLEX WITH A PHOSPHONATE INHIBITOR IVA-VAL-VAL-LEU(P)-(O)PHE-ALA-ALA-OME |
1RNE | A:171-325; A:1-170 | THE CRYSTAL STRUCTURE OF RECOMBINANT GLYCOSYLATED HUMAN RENIN ALONE AND IN COMPLEX WITH A TRANSITION STATE ANALOG INHIBITOR |
1SGZ | A:14-146; A:147-385; B:147-385; C:147-385; D:147-385; B:14-146; C:14-146; D:14-146 | CRYSTAL STRUCTURE OF UNBOUND BETA-SECRETASE CATALYTIC DOMAIN. |
1TQF | A:14-146; A:147-385 | CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH INHIBITOR |
1W50 | A:14-146; A:147-385 | APO STRUCTURE OF BACE (BETA SECRETASE) |
1W51 | A:14-146; A:147-385 | BACE (BETA SECRETASE) IN COMPLEX WITH A NANOMOLAR NON-PEPTIDIC INHIBITOR |
1XN2 | A:14-146; B:14-146; A:147-385; B:147-385; C:147-385; D:147-385; C:14-146; D:14-146 | NEW SUBSTRATE BINDING POCKETS FOR BETA-SECRETASE. |
1XN3 | A:14-146; A:147-385; B:147-385; C:147-385; D:147-385; B:14-146; C:14-146; D:14-146 | CRYSTAL STRUCTURE OF BETA-SECRETASE BOUND TO A LONG INHIBITOR WITH ADDITIONAL UPSTREAM RESIDUES. |
1XS7 | D:14-146; D:147-385 | CRYSTAL STRUCTURE OF A CYCLOAMIDE-URETHANE-DERIVED NOVEL INHIBITOR BOUND TO HUMAN BRAIN MEMAPSIN 2 (BETA-SECRETASE). |
1YM2 | A:14-146; A:147-385; C:147-385; B:147-385; B:14-146; C:14-146 | CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH NVP-AUR200 |
1YM4 | A:14-146; B:14-146; C:14-146; B:147-385; A:147-385; C:147-385 | CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH NVP-AMK640 |
2B8L | A:14-146; A:147-385 | CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH INHIBITOR |
2B8V | A:14-146; A:147-385 | CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE COMPLEXED WITH L-L000430,469 |
2EWY | A:30-162; B:30-162; C:30-162; D:30-162; A:163-398; B:163-398; C:163-398; D:163-398 | CRYSTAL STRUCTURE OF HUMAN BACE2 IN COMPLEX WITH A HYDROXYETHYLENAMINE TRANSITION-STATE INHIBITOR |
2F3E | A:14-146; A:147-385; B:147-385; C:147-385; B:14-146; C:14-146 | CRYSTAL STRUCTURE OF THE BACE COMPLEX WITH AXQ093, A MACROCYCLIC INHIBITOR |
2F3F | A:14-146; B:14-146; C:14-146; A:147-385; B:147-385; C:147-385 | CRYSTAL STRUCTURE OF THE BACE COMPLEX WITH BDF488, A MACROCYCLIC INHIBITOR |
2FDP | A:14-146; B:14-146; C:14-146; B:147-385; A:147-385; C:147-385 | CRYSTAL STRUCTURE OF BETA-SECRETASE COMPLEXED WITH AN AMINO-ETHYLENE INHIBITOR |
2FS4 | A:175-332; B:175-332; A:3-174; B:3-174 | KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING |
2G1N | A:177-334; B:177-334; A:3-176; B:3-176 | KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE "C" RING |
2G1O | A:177-334; B:177-334; A:3-176; B:3-176 | KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE "C" RING |
2G1R | A:177-334; B:177-334; A:3-176; B:3-176 | KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING |
2G1S | A:177-334; B:177-334; A:3-176; B:3-176 | KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING |
2G1Y | A:177-334; B:177-334; A:3-176; B:3-176 | KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE "C" RING |
2G20 | A:177-334; B:177-334; A:3-176; B:3-176 | KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING |
2G21 | A:175-332; B:175-332; A:3-174; B:3-174 | KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE "C" RING |
2G22 | A:177-334; B:177-334; A:3-176; B:3-176 | KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE "C" RING |
2G24 | A:175-332; B:175-332; A:3-174; B:3-174 | KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE "C" RING |
2G26 | A:175-332; B:175-332; A:3-174; B:3-174 | KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE "C" RING |
2G27 | A:175-332; B:175-332; A:3-174; B:3-174 | KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE "C" RING |
2G94 | A:14-146; B:14-146; C:14-146; D:14-146; A:147-385; B:147-385; C:147-385; D:147-385 | CRYSTAL STRUCTURE OF BETA-SECRETASE BOUND TO A POTENT AND HIGHLY SELECTIVE INHIBITOR. |
2HIZ | A:14-146; B:14-146; C:14-146; A:147-385; B:147-386; C:147-386 | CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE (BACE) IN THE PRESENCE OF AN INHIBITOR |
2HM1 | A:14-146; A:147-386 | CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE (BACE) IN THE PRESENCE OF AN INHIBITOR (2) |
2I4Q | A:177-335; B:177-335; A:0-176; B:0-176 | HUMAN RENIN/PF02342674 COMPLEX |
2IQG | A:14-146; A:147-386 | CRYSTAL STRUCTURE OF HYDROXYETHYL SECONDARY AMINE-BASED PEPTIDOMIMETIC INHIBITOR OF HUMAN BETA-SECRETASE (BACE) |
2IRZ | A:14-146; A:147-385 | CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE COMPLEXED WITH INHIBITOR |
2IS0 | A:14-146; A:147-385 | CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE COMPLEXED WITH INHIBITOR |
2NTR | A:14-146; A:147-385 | CRYSTAL STRUCTURE OF HUMAN BACE-1 BOUND TO INHIBITOR |
2OAH | A:14-146; A:147-385 | CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH INHIBITOR |
2OF0 | A:14-146; A:147-385 | X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 5 |
2OHK | A:14-146; A:147-385 | X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH 1-AMINO-ISOQUINOLINE |
2OHL | A:14-146; A:147-385 | X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH 2-AMINOQUINOLINE |
2OHM | A:14-146; A:147-385 | X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH N~3~-BENZYLPYRIDINE-2,3-DIAMINE |
2OHN | A:14-146; A:147-385 | X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH 4-(4-FLUOROBENZYL)PIPERIDINE |
2OHP | A:14-146; A:147-385 | X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 3 |
2OHQ | A:14-146; A:147-385 | X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 4 |
2OHR | A:14-146; A:147-385 | X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 6A |
2OHS | A:14-146; A:147-385 | X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 6B |
2OHT | A:14-146; A:147-385 | X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 7 |
2OHU | A:14-146; A:147-385 | X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 8B |
2P4J | A:14-146; B:14-146; C:14-146; D:14-146; A:147-385; B:147-385; C:147-385; D:147-385 | CRYSTAL STRUCTURE OF BETA-SECRETASE BOND TO AN INHIBITOR WITH ISOPHTHALAMIDE DERIVATIVES AT P2-P3 |
2P83 | A:14-146; B:14-146; C:14-146; A:147-385; B:147-386; C:147-386 | POTENT AND SELECTIVE ISOPHTHALAMIDE S2 HYDROXYETHYLAMINE INHIBITOR OF BACE1 |
2P8H | A:14-146; A:147-385 | CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH INHIBITOR |
2PH6 | A:14-146; A:147-385 | CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH INHIBITOR |
2PH8 | A:14-146; A:147-385 | CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH INHIBITOR |
2Q11 | A:14-146; B:14-146; C:14-146; A:147-385; B:147-385; C:147-385 | STRUCTURE OF BACE COMPLEXED TO COMPOUND 1 |
2Q15 | A:14-146; A:147-385 | STRUCTURE OF BACE COMPLEXED TO COMPOUND 3A |
2QK5 | A:75-207; B:208-446; A:208-447; B:75-207 | STRUCTURE OF BACE1 BOUND TO SCH626485 |
2QMD | A:75-207; B:208-446; A:208-447; B:75-207 | STRUCTURE OF BACE BOUND TO SCH722924 |
2QMF | A:75-207; B:75-207; B:208-446; A:208-447 | STRUCTURE OF BACE BOUND TO SCH735310 |
2QMG | A:75-207; B:75-207; B:208-446; A:208-447 | STRUCTURE OF BACE BOUND TO SCH745966 |
2QP8 | A:75-207; B:75-207; B:208-446; A:208-447 | STRUCTURE OF BACE BOUND TO SCH734723 |
2QU2 | A:76-208; A:209-445 | BACE1 WITH COMPOUND 1 |
2QU3 | A:76-208; A:209-445 | BACE1 WITH COMPOUND 2 |
2QZK | A:14-146; A:147-385 | CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH I21 |
2QZL | A:14-146; A:147-385 | CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH IXS |
2REN | A:182-337; A:7-181 | STRUCTURE OF RECOMBINANT HUMAN RENIN, A TARGET FOR CARDIOVASCULAR-ACTIVE DRUGS, AT 2.5 ANGSTROMS RESOLUTION |
2VA5 | A:14-146; A:147-386 | X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 8C |
2VA7 | A:14-146; A:147-386 | X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 27 |
2VIE | A:75-207; A:208-447 | HUMAN BACE-1 IN COMPLEX WITH N-((1S,2R)-1-BENZYL-2-HYDROXY-3-((1,1,5-TRIMETHYLHEXYL)AMINO)PROPYL)-3-(ETHYLAMINO)-5-(2-OXOPYRROLIDIN-1-YL)BENZAMIDE |
2VIJ | A:75-207; A:208-447 | HUMAN BACE-1 IN COMPLEX WITH 3-(1,1-DIOXIDOTETRAHYDRO-2H-1, 2-THIAZIN-2-YL)-5-(ETHYLAMINO)-N-((1S,2R)-2-HYDROXY-1-( PHENYLMETHYL)-3-(1,2,3,4-TETRAHYDRO-1-NAPHTHALENYLAMINO) PROPYL)BENZAMIDE |
2VIY | A:75-207; A:208-447 | HUMAN BACE-1 IN COMPLEX WITH N-((1S,2R)-3-(((1S)-2-( CYCLOHEXYLAMINO)-1-METHYL-2-OXOETHYL)AMINO)-2-HYDROXY-1-( PHENYLMETHYL)PROPYL)-3-(PENTYLSULFONYL)BENZAMIDE |
2VIZ | A:75-207; A:208-447 | HUMAN BACE-1 IN COMPLEX WITH N-((1S,2R)-3-(((1S)-2-( CYCLOHEXYLAMINO)-1-METHYL-2-OXOETHYL)AMINO)-2-HYDROXY-1-( PHENYLMETHYL)PROPYL)-3-(2-OXO-1-PYRROLIDINYL)-5-(PROPYLOXY) BENZAMIDE |
2VJ6 | A:75-207; A:208-447 | HUMAN BACE-1 IN COMPLEX WITH N-((1S,2R)-3-(((1S)-2-( CYCLOHEXYLAMINO)-1-METHYL-2-OXOETHYL)AMINO)-2-HYDROXY-1-( PHENYLMETHYL)PROPYL)-3-(ETHYLAMINO)-5-(2-OXO-1-PYRROLIDINYL)BENZAMIDE |
2VJ7 | A:75-207; A:208-447 | HUMAN BACE-1 IN COMPLEX WITH 3-(ETHYLAMINO)-N-((1S,2R)-2-HYDROXY-1-(PHENYLMETHYL)-3-(((3-(TRIFLUOROMETHYL)PHENYL) METHYL)AMINO)PROPYL)-5-(2-OXO-1-PYRROLIDINYL)BENZAMIDE |
2VJ9 | A:75-207; A:208-451 | HUMAN BACE-1 IN COMPLEX WITH N-((1S,2R)-3-(CYCLOHEXYLAMINO)-2-HYDROXY-1-(PHENYLMETHYL)PROPYL)-3-(ETHYLAMINO)-5-(2-OXO-1-PYRROLIDINYL)BENZAMIDE |
2VKM | A:14-146; A:147-385; B:147-385; C:147-385; D:147-385; B:14-146; C:14-146; D:14-146 | CRYSTAL STRUCTURE OF GRL-8234 BOUND TO BACE (BETA-SECRETASE) |
2VNM | A:75-207; A:208-447 | HUMAN BACE-1 IN COMPLEX WITH 3-(1,1-DIOXIDOTETRAHYDRO-2H-1, 2-THIAZIN-2-YL)-5-(ETHYLAMINO)-N-((1S,2R)-2-HYDROXY-1-( PHENYLMETHYL)-3-(((3-(TRIFLUOROMETHYL)PHENYL)METHYL)AMINO) PROPYL)BENZAMIDE |
2VNN | A:75-207; A:208-447 | HUMAN BACE-1 IN COMPLEX WITH 7-ETHYL-N-((1S,2R)-2-HYDROXY-1-(PHENYLMETHYL)-3-(((3-(TRIFLUOROMETHYL)PHENYL)METHYL)AMINO) PROPYL)-1-METHYL-3,4-DIHYDRO-1H-(1,2,5)THIADIAZEPINO(3,4,5-HI)INDOLE-9-CARBOXAMIDE 2,2-DIOXIDE |
2WEZ | A:75-207; A:208-447 | HUMAN BACE-1 IN COMPLEX WITH 1-ETHYL-N-((1S,2R)-2-HYDROXY-3-(((3-(METHYLOXY)PHENYL)METHYL)AMINO)-1-(PHENYLMETHYL) PROPYL)-4-(2-OXO-1-PYRROLIDINYL)-1H-INDOLE-6-CARBOXAMIDE |
2WF0 | A:75-207; A:208-447 | HUMAN BACE-1 IN COMPLEX WITH 4-ETHYL-N-((1S,2R)-2-HYDROXY-1-(PHENYLMETHYL)-3-(((3-(TRIFLUOROMETHYL)PHENYL)METHYL)AMINO) PROPYL)-8-(2-OXO-1-PYRROLIDINYL)-6-QUINOLINECARBOXAMIDE |
2WF1 | A:75-207; A:208-447 | HUMAN BACE-1 IN COMPLEX WITH 7-ETHYL-N-((1S,2R)-2-HYDROXY-3-(((3-(METHYLOXY)PHENYL(METHYL)AMINO)-1-(PHENYLMETHYL) PROPYL)-1-METHYL-3,4-DIHYDRO-1H-(1,2,5)THIADIAZEPINO(3,4,5-HI)INDOLE-9-CARBOXAMIDE 2,2-DIOXIDE |
2WF2 | A:75-207; A:208-447 | HUMAN BACE-1 IN COMPLEX WITH 8-ETHYL-N-((1S,2R)-2-HYDROXY-3-(((3-(METHYLOXY)PHENYL)METHYL)AMINO)-1-(PHENYLMETHYL) PROPYL)-1-METHYL-3,4,7,8-TETRAHYDRO-1H,6H-(1,2,5) THIADIAZEPINO(5,4,3-DE)QUINOXALINE-10-CARBOXAMIDE 2,2-DIOXIDE |
2WF3 | A:75-207; A:208-447 | HUMAN BACE-1 IN COMPLEX WITH 6-(ETHYLAMINO)-N-((1S,2R)-2-HYDROXY-3-(((3-(METHYLOXY)PHENYL)METHYL)AMINO)-1-(PHENYLMETHYL)PROPYL)-1-METHYL-1, 3,4,5-TETRAHYDRO-2,1-BENZOTHIAZEPINE-8-CARBOXAMIDE 2,2-DIOXIDE |
2WF4 | A:75-207; A:208-447 | HUMAN BACE-1 IN COMPLEX WITH 6-ETHYL-1-METHYL-N-((1S)-2-OXO-1-(PHENYLMETHYL)-3-(TETRAHYDRO-2H-PYRAN-4-YLAMINO)PROPYL)-1,3,4,6-TETRAHYDRO(1,2)THIAZEPINO(5,4,3-CD)INDOLE-8-CARBOXAMIDE 2,2-DIOXIDE |
2WJO | A:14-146; A:147-388 | HUMAN BACE (BETA SECRETASE) IN COMPLEX WITH CYCLOHEXANECARBOXYLIC ACID (2-(2-AM INO-6-PHENOXY-4H-QUINAZOLIN-3-YL)-2-CYCLOHEXYL-ETHYL)-AMIDE |
2XFI | A:75-207; A:208-447 | HUMAN BACE-1 IN COMPLEX WITH N-((1S,2R)-3-(((1S)-2-( CYCLOHEXYLAMINO)-1-METHYL-2-OXOETHYL)AMINO)-2-HYDROXY-1-( PHENYLMETHYL)PROPYL)-3-((METHYLSULFONYL)(PHENYL)AMINO) BENZAMIDE |
2XFJ | A:75-207; A:208-447 | HUMAN BACE-1 IN COMPLEX WITH N-((1S,2R)-3-(((1S)-2-( CYCLOHEXYLAMINO)-1-METHYL-2-OXOETHYL)AMINO)-2-HYDROXY-1-( PHENYLMETHYL)PROPYL)-3-(ETHYLAMINO)-5-(2-OXO-1-PYRROLIDINYL)BENZAMIDE |
2XFK | A:75-207; A:208-447 | HUMAN BACE-1 IN COMPLEX WITH N-((1S,2R)-3-(((1S)-2-( CYCLOHEXYLAMINO)-1-METHYL-2-OXOETHYL)AMINO)-2-HYDROXY-1-( PHENYLMETHYL)PROPYL)-3-(ETHYLAMINO)-5-((METHYLSULFONYL)( PHENYL)AMINO)BENZAMIDE |
2ZDZ | A:76-208; A:209-446 | X-RAY STRUCTURE OF BACE-1 IN COMPLEX WITH COMPOUND 3.B.10 |
2ZE1 | A:76-208; A:209-446 | X-RAY STRUCTURE OF BACE-1 IN COMPLEX WITH COMPOUND 6G |
2ZHR | A:14-146; B:14-146; B:147-385; A:147-385 | CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH OM99-2 AT PH 5.0 |
2ZHS | A:14-146; A:147-385 | CRYSTAL STRUCTURE OF BACE1 AT PH 4.0 |
2ZHT | A:14-146; A:147-385 | CRYSTAL STRUCTURE OF BACE1 AT PH 4.5 |
2ZHU | A:14-146; A:147-385 | CRYSTAL STRUCTURE OF BACE1 AT PH 5.0 |
2ZHV | A:14-146; A:147-385 | CRYSTAL STRUCTURE OF BACE1 AT PH 7.0 |
2ZJH | A:14-146; A:147-385 | CRYSTAL STRUCTURE OF THE HUMAN BACE1 CATALYTIC DOMAIN IN COMPLEX WITH N-(1-BENZYL-PIPERIDIN-4-YL)-4-MERCAPTO-BUTYRAMIDE |
2ZJI | A:14-146; A:147-385 | CRYSTAL STRUCTURE OF THE HUMAN BACE1 CATALYTIC DOMAIN IN COMPLEX WITH N-[1-(2,6-DIMETHOXY-BENZYL)-PIPERIDIN-4-YL]-4-MERCAPTO-BUTYRAMIDE |
2ZJJ | A:14-146; A:147-385 | CRYSTAL STRUCTURE OF THE HUMAN BACE1 CATALYTIC DOMAIN IN COMPLEX WITH 4-(4-FLUORO-BENZYL)-PIPERAZINE-2-CARBOXYLIC ACID (2-MERCAPTO-ETHYL)-AMIDE |
2ZJK | A:14-146; B:14-146; C:14-146; B:147-385; A:147-385; C:147-385 | CRYSTAL STRUCTURE OF THE HUMAN BACE1 CATALYTIC DOMAIN IN COMPLEX WITH 4-(4-FLUORO-BENZYL)-PIPERAZINE-2-CARBOXYLIC ACID(3-MERCAPTO-PROPYL)-AMIDE |
2ZJL | A:14-146; A:147-385 | CRYSTAL STRUCTURE OF THE HUMAN BACE1 CATALYTIC DOMAIN IN COMPLEX WITH N-[1-(5-BROMO-2,3-DIMETHOXY-BENZYL)-PIPERIDIN-4-YL]-4-MERCAPTO-BUTYRAMIDE |
2ZJM | A:14-146; A:147-385 | CRYSTAL STRUCTURE OF THE HUMAN BACE1 CATALYTIC DOMAIN IN COMPLEX WITH N-[1-(5-CHLORO-2-ISOPROPOXY-3-METHOXY-BENZYL)-PIPERIDIN-4-YL]-2-(4-SULFAMOYL-PHENOXY)-ACETAMIDE |
2ZJN | A:14-146; A:147-385 | CRYSTAL STRUCTURE OF THE HUMAN BACE1 CATALYTIC DOMAIN IN COMPLEX WITH N-[1-(5-CHLORO-2-ISOPROPOXY-3-METHOXY-BENZYL)-PIPERIDIN-4-YL]-2-(2-METHYL-4-SULFAMOYL-PHENOXY)-ACETAMIDE |
3BRA | A:14-146; A:147-386 | BACE-1 COMPLEXED WITH COMPOUND 1 |
3BUF | A:14-146; A:147-386 | BACE-1 COMPLEXED WITH COMPOUND 2 |
3BUG | A:14-146; A:147-386 | BACE-1 COMPLEXED WITH COMPOUND 3 |
3BUH | A:14-146; A:147-386 | BACE-1 COMPLEXED WITH COMPOUND 4 |
3CIB | A:75-207; B:75-207; B:208-446; A:208-447 | STRUCTURE OF BACE BOUND TO SCH727596 |
3CIC | A:75-207; B:75-207; B:208-446; A:208-447 | STRUCTURE OF BACE BOUND TO SCH709583 |
3CID | A:75-207; B:75-207; B:208-446; A:208-447 | STRUCTURE OF BACE BOUND TO SCH726222 |
3CKP | A:14-146; B:14-146; C:14-146; C:147-386; A:147-386; B:147-386 | CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH INHIBITOR |
3CKR | A:14-146; B:14-146; C:14-146; C:147-386; A:147-386; B:147-386 | CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH INHIBITOR |
3DM6 | A:14-146; B:14-146; C:14-146; C:147-385; B:147-385; A:147-385 | BETA-SECRETASE 1 COMPLEXED WITH STATINE-BASED INHIBITOR |
3EXO | A:14-146; A:147-385 | CRYSTAL STRUCTURE OF BACE1 BOUND TO INHIBITOR |
3FKT | A:34-166; A:167-403 | CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH SPIROPIPERDINE IMINOHYDANTOIN INHIBITOR |
3GW5 | A:182-339; B:182-339; B:7-181; A:7-181 | CRYSTAL STRUCTURE OF HUMAN RENIN COMPLEXED WITH A NOVEL INHIBITOR |
3H0B | A:14-146; B:14-146; C:14-146; A:147-385; B:147-385; C:147-385 | DISCOVERY OF AMINOHETEROCYCLES AS A NOVEL BETA-SECRETASE INHIBITOR CLASS |
3HVG | A:14-146; B:14-146; C:14-146; B:147-385; C:147-385; A:147-385 | STRUCTURE OF BACE (BETA SECRETASE) IN COMPLEX WITH EV0 |
3HW1 | A:14-146; C:14-146; B:14-146; A:147-385; B:147-385; C:147-385 | STRUCTURE OF BACE (BETA SECRETASE) IN COMPLEX WITH LIGAND EV2 |
3I25 | A:14-146; A:147-385; B:147-385; C:147-385; B:14-146; C:14-146 | POTENT BETA-SECRETASE 1 HYDROXYETHYLENE INHIBITOR |
3IGB | A:76-208; A:209-447 | BACE-1 WITH COMPOUND 3 |
3IN3 | A:76-208; A:209-446 | BACE1 WITH COMPOUND 30 |
3IN4 | A:76-208; A:209-446 | BACE1 WITH COMPOUND 38 |
3IND | A:76-208; A:209-448 | BACE1 WITH THE AMINOHYDANTOIN COMPOUND 29 |
3INE | A:76-208; A:209-447 | BACE1 WITH THE AMINOHYDANTOIN COMPOUND S-34 |
3INF | A:76-208; A:209-448 | BACE1 WITH THE AMINOHYDANTOIN COMPOUND 37 |
3INH | A:76-208; A:209-448 | BACE1 WITH THE AMINOHYDANTOIN COMPOUND R-58 |
3IVH | A:75-207; A:208-447 | DESIGN AND SYNTHESIS OF POTENT BACE-1 INHIBITORS WITH CELLULAR ACTIVITY: STRUCTURE-ACTIVITY RELATIONSHIP OF P1 SUBSTITUENTS |
3IVI | A:75-207; C:208-447; B:208-447; A:208-447; B:75-207; C:75-207 | DESIGN AND SYNTHESIS OF POTENT BACE-1 INHIBITORS WITH CELLULAR ACTIVITY: STRUCTURE-ACTIVITY RELATIONSHIP OF P1 SUBSTITUENTS |
3IXJ | A:62-194; C:195-433; A:195-433; B:195-433; B:62-194; C:62-194 | CRYSTAL STRUCTURE OF BETA-SECRETASE 1 IN COMPLEX WITH SELECTIVE BETA-SECRETASE 1 INHIBITOR |
3K5C | A:14-146; A:147-385; B:147-385; C:147-385; B:14-146; C:14-146 | HUMAN BACE-1 COMPLEX WITH NB-216 |
3K5D | A:14-146; B:14-146; C:14-146; A:147-385; B:147-385; C:147-386 | CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH AHM178 |
3K5F | A:14-146; B:14-146; C:14-146; A:147-385; B:147-385; C:147-385 | HUMAN BACE-1 COMPLEX WITH AYH011 |
3K5G | A:14-146; A:147-385; B:147-385; C:147-385; B:14-146; C:14-146 | HUMAN BACE-1 COMPLEX WITH BJC060 |
3KM4 | A:182-339; B:182-339; B:7-181; A:7-181 | OPTIMIZATION OF ORALLY BIOAVAILABLE ALKYL AMINE RENIN INHIBITORS |
3KMX | A:75-207; B:208-446; A:208-447; B:75-207 | STRUCTURE OF BACE BOUND TO SCH346572 |
3KMY | A:75-207; B:208-446; A:208-447; B:75-207 | STRUCTURE OF BACE BOUND TO SCH12472 |
3KN0 | B:75-207; B:208-446; A:208-447; A:75-207 | STRUCTURE OF BACE BOUND TO SCH708236 |
3L38 | A:76-208; A:209-445 | BACE1 IN COMPLEX WITH THE AMINOPYRIDINE COMPOUND 44 |
3L3A | A:76-208; A:209-446 | BACE-1 WITH THE AMINOPYRIDINE COMPOUND 32 |
3L58 | A:75-207; B:75-207; B:208-446; A:208-447 | STRUCTURE OF BACE BOUND TO SCH589432 |
3L59 | A:75-207; B:208-446; A:208-447; B:75-207 | STRUCTURE OF BACE BOUND TO SCH710413 |
3L5B | A:75-207; B:75-207; B:208-446; A:208-447 | STRUCTURE OF BACE BOUND TO SCH713601 |
3L5C | B:75-207; A:75-207; B:208-446; A:208-447 | STRUCTURE OF BACE BOUND TO SCH723871 |
3L5D | B:75-207; A:75-207; B:208-446; A:208-447 | STRUCTURE OF BACE BOUND TO SCH723873 |
3L5E | A:75-207; B:75-207; B:208-446; A:208-447 | STRUCTURE OF BACE BOUND TO SCH736062 |
3L5F | A:75-207; B:75-207; B:208-446; A:208-447 | STRUCTURE OF BACE BOUND TO SCH736201 |